Mobile

A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hy...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005569-12

A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To assess the safety and tolerability of oral STI571 compared with placebo in patients with pulmonary arterial hypertension. • To evaluate efficacy of oral STI571 as measured by improvement in 6-minute walk test.

Critère d'inclusion

  • pulmonary arterial hypertension

Liens